WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for single-cell analysis and clinical research in the United States, Canada, Europe, and the Asia Pacific. It offers SmartChip Real-Time polymerase chain reaction (PCR) system, which provides a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of PCR. The company’s SmartChip Real-Time PCR system consists of two instrumentation components comprising a SmartChip MultiSample NanoDispenser for applying sample, assay, and reaction mix to the SmartChip Panels; and a SmartChip Cycler for thermal cycling and collecting data from the real-time PCR assays. It also provides SmartChip Single-Cell Isolation System, which isolates thousands of single cells and processes specific cells for analysis; SmartChip Target Enrichment system that amplifies the targets of interest through PCR; and Apollo 324TM library preparation System, a walk-away automation platform that offers DNA, RNA-Seq, and ChIP-Seq library preparation kits for analysis on NGS platforms. The company focuses on providing its products to researchers who perform genetic analysis and cell biology, primarily at pharmaceutical and biotech companies; academic and private research centers; and diagnostics companies involved in biomarker research. WaferGen Bio-systems, Inc. was founded in 2002 and is headquartered in Fremont, California. As of February 28, 2017, WaferGen Bio-systems, Inc. operates as a subsidiary of Takara Bio USA Holdings, Inc.